This list contains references from the content that can be linked to their source. For a full set of references and notes please see the PDF or HTML where available.
RobsonM, LevinD, FedericiJ, et al. Breast conservation therapy for invasive breast cancer in Ashkenazi women with BRCA gene founder mutations. J Natl Cancer Inst1999; 91: 2112–2117.
RobsonME, ChappuisPO, SatagopanJ, WongN, BoydJ, GoffinJR, HudisC, RobergeD, NortonL, BeginLR, OffitK, FoulkesWD. A combined analysis of outcome following breast cancer: differences in survival based on BRCA1/BRCA2 mutation status and administration of adjuvant treatment. Breast Cancer Res2004; 6(1): R8–R17.
HafftyBG, HarroldE, KnanAJ, et al. Outcome of conservatively managed early-onset breast cancer by BRCA1/2 status. Lancet2002; 359: 1471–1477.
FisherB, AndersonS, BryantJ, et al. Twenty-year follow-up of a randomized trial comparing total mastectomy, lumpectomy, and lumpectomy plus irradiation for the treatment of invasive breast cancer. New Engl J Med2002; 347: 1233–1241.
VeronesiU, CascinelliN, MarianiL, et al. Twenty-year follow-up of a randomized study comparing breast- conserving surgery with radical mastectomy for early breast cancer. New Engl J Med2002; 347: 1227–1232.
ClausEB, SchildkrantJM, ThompsonWD, et al. The genetic attributable risk of breast and ovarian cancer. Cancer1996; 77: 2318–2324.
XiaF, PowellS. The molecular basis of radiosensitivity and chemosensitivity in the treatment of breast cancer. Semin Radiat Oncol2002; 12: 296–304.
HallJM, LeeMK, NewmanB, et al. Linkage of early onset familial breast cancer to chromosome 17q21. Science1990; 250: 1684–1689.
WoosterR, NeuhausenSL, MangionJ, et al. Localization of a breast cancer susceptibility gene, BRCA2, to chromosome 13q12-13. Science1994; 265: 2088–2090.
BuchholzTA, WazerDE. Molecular biology and genetics of breast cancer development: a clinical perspective. Semin Radiat Oncol2002: 12: 285–295.
ZhongQ, ChenCF, LiS, et al. Association of BRCA1 with the hRad50-hMre11-p95 complex and the DNA damage response. Science1999; 285: 747–750.
XuB, KimS, KastanMB. Involvement of BRCA1 in S-phase and G(2)-phase checkpoints after ionizing irradiation. Mol Cell Biol2001; 21: 3445–3450.
XuX, WeaverZ, LinkeSP, et al. Centrosome amplification and a defective G2-M cell cycle checkpoint induce genetic instability in BRCA1 exon 11 isoform-deficient cells. Mol Cell1999; 3: 389–395.
SharanSK, MorimatsuM, AlbrechtU, et al. Embryonic lethality and radiation hypersensitivity mediated by Rad51 in mice lacking Brca2. Nature1997; 386: 804–810.
ShenS, WeaverZ, XuX, et al. A targeted disruption of the murine BRCA1 gene causes γ-irradiation hypersensitivity and genetic instability. Oncogene1998; 17: 3115–3124.
PorterDE, CohenBB, WallaceMR, et al. Breast cancer incidence, penetrance, and survival in probable carriers of BRCA1 gene mutation in families linked to BRCA1 on chromosome 17q12-21. Br J Surg1994; 81: 1512–1515.
FordD, EastonDF, StrattonM, et al. Genetic heterogeneity and penetrance analysis of the BRCA1 and BRCA2 genes in breast cancer families: The Breast Cancer Linkage Consortium. Am J Hum Genet1998; 62: 676–689.
JacquemierJ, EisingerF, BirnbaumD, et al. Histoprognostic grade in BRCA1-associated breast cancer. Lancet1995; 345: 1503.
MarcusJN, WatsonP, PageDL, et al. Hereditary breast cancer: pathobiology, prognosis, and BRCA1 and BRCA2 gene linkage. Cancer1996; 77: 697–709.
VerhoogLC, BrekelmansCTM, SeynaeveC, et al. Survival and tumor characteristics of breast-cancer patients with germline mutations of BRCA1. Lancet1998; 351: 316–321.
FordD, EastonDF, BishopDT, et al. Risks of cancer in BRCA1-mutation carriers. Lancet1994; 343: 692–695.
FordD, EastonDF. The genetics of breast an ovarian cancer. Br J Cancer1995; 72: 805–812.
CoxJD, StetzJ, PajakTF. Toxicity criteria of the Radiation Oncology Group (RTOG) and the European Organization for Research and Treatment of Cancer (EORTC). Int J Radiat Oncol Biol Phys1995; 31: 1341–1346.
FisherB, ConstantinoJP, WickerhamDL, et al. Tamoxifen for prevention of breast cancer; report of the National Surgical Adjuvant Breast and Bowel Project P1 study. J Natl Cancer Inst1998; 90: 1371–1388.
RebbeckTR, LevinAM, EisenA, et al. Breast cancer risk after bilateral prophylactic oophorectomy in BRCA1 mutation carriers. J Natl Cancer Inst1999; 91: 1475–1479.
RebbeckTR, LynchHT, NeuhausenSL, et al. Prophylactic oophorectomy in carriers of BRCA1 or BRCA2 mutations. New Engl J Med2002; 346: 1616–1622.
KauffND, SatagopanJM, RobsonME, et al. Risk-reducing salpingo-oophorectomy in women with a BRCA1 or BRCA2 mutation. New Engl J Med2002; 346: 1609–1615.
KingM, WieandS, HaleK, et al. Tamoxifen and breast cancer incidence among women with inherited mutations in BRCA1 and BRCA2. J Am Med Assoc2001; 286: 2251–2256.
NarodSA, BrunetJ, GhadirianP, et al. Tamoxifen and risk of contralateral breast cancer in BRCA1 and BRCA2 mutation carriers: a case control study. Lancet2000; 356: 1876–1881.